NCT05185089: A trial that was reported late by Nerre Therapeutics Ltd.
This trial has reported, although it was 105 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT05185089 |
|---|---|
| Title | A Double-Blind, Randomised, Placebo Controlled, Two Period Cross-Over Study to Evaluate the Efficacy and Safety of Orvepitant in Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 1, 2022 |
| Completion date | June 5, 2024 |
| Required reporting date | June 5, 2025, midnight |
| Actual reporting date | Sept. 18, 2025 |
| Date last checked at ClinicalTrials.gov | May 21, 2026 |
| Days late | 105 |